HK Stock Market Move | ASCLETIS-B (01672) rose more than 11%, with its stock price increasing by 1.2 times in the past month. The company has been actively laying out in the fields of MASH and weight loss competitions.

ASCLETIS-B (01672) rose more than 11%, reaching a high of 3.56 Hong Kong dollars, the highest since February 2023. The stock price has more than doubled since early December last year. As of press time, it rose by 11.15%, to 3.49 Hong Kong dollars, with a turnover of 10.5361 million Hong Kong dollars. EB SECURITIES pointed out that the company is currently researching multiple weight-loss related drugs. In addition to ASC47, it is also advancing clinical trials of ASC30's daily oral formulation and monthly subcutaneous injection formulation, the latter being a small molecule GLP-1R agonist. Both the oral and subcutaneous formulations of ASC30 are currently undergoing Phase 1 clinical trials in the United States, with top-line data expected to be announced in the first quarter of 2025. The company is actively laying out in the MASH and weight-loss track, with progress at the forefront in China. Guotai Junan International stated that the company is an innovative R&D-driven biotechnology company, with smooth progress in the research and development of ASC47 and ASC30 for the treatment of obesity, and vast market potential. The ASC40 product pipeline research and development for acne/MASH/brain glioma is progressing well, with Phase III clinical trials for acne starting in December 2023. The company will conduct Business Development (BD) when positive data is obtained from Phase III clinical trials, promoting significant growth in the company's performance and cash flow.